Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Amit Sanyal, MD: A Clinician’s Perspective

Apr

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David A. Hyman, MD, JD, on Inclusive Shared Savings

Amit Sanyal, MD: A Clinician’s Perspective

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

ACP Issues Controversial New Breast Cancer Screening Guidelines

Educational Disparities in Young-Onset Colorectal Cancer Mortality

Breast Cancer Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxicity